Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus DOS neoadjuvant for gastric cancer
NCT06475417Phase 2Recruiting
- Sponsor
- Tangdu Hospital
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in gastric cancer (GC), sponsored by Tangdu Hospital. Started May 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06475417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06475417.